Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Operating Leases (2019 - 2023)

Historic Operating Leases for Marker Therapeutics (MRKR) over the last 5 years, with Q1 2023 value amounting to $6.8 million.

  • Marker Therapeutics' Operating Leases fell 4177.77% to $6.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was $6.8 million, marking a year-over-year decrease of 4177.77%. This contributed to the annual value of $7.0 million for FY2022, which is 3741.67% down from last year.
  • Per Marker Therapeutics' latest filing, its Operating Leases stood at $6.8 million for Q1 2023, which was down 4177.77% from $7.0 million recorded in Q4 2022.
  • Over the past 5 years, Marker Therapeutics' Operating Leases peaked at $12.2 million during Q3 2020, and registered a low of $280247.0 during Q4 2019.
  • Its 5-year average for Operating Leases is $7.5 million, with a median of $9.5 million in 2020.
  • As far as peak fluctuations go, Marker Therapeutics' Operating Leases soared by 413499.27% in 2020, and later crashed by 4177.77% in 2023.
  • Over the past 5 years, Marker Therapeutics' Operating Leases (Quarter) stood at $280247.0 in 2019, then surged by 4134.99% to $11.9 million in 2020, then fell by 5.23% to $11.2 million in 2021, then crashed by 37.42% to $7.0 million in 2022, then fell by 3.06% to $6.8 million in 2023.
  • Its Operating Leases stands at $6.8 million for Q1 2023, versus $7.0 million for Q4 2022 and $7.2 million for Q3 2022.